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Abstract
Brugada syndrome is an inherited channelopathy associated with an increased risk of syncope 
and sudden cardiac death. In rare cases it can be manifested with electrical storm. We report 
two  cases  of  Brugada  syndrome  that  presented  with  electrical  storm  and  were  treated 
successfully  with oral  quinidine,  an "endangered species"  drug.                          
Introduction
Brugada syndrome (BS) is an inherited channelopathy characterized electrocardiographically 
by pseudo-right bundle branch block pattern and ST segment elevation in precordial leads V1-
3 [1].  The clinical  manifestation of BS varies from asymptomatic  form to sudden cardiac 
death [1]. We report two cases of BS that were presented with electrical storm.             
Case  1                                              
A 38-year-old man with BS, who was treated with ICD implantation two years ago following 
an  episode  of  syncope  and  a  subsequent  positive  procainamide  test,  presented  to  our 
emergency department with electrical storm (i.e. three episodes of ventricular tachycardia in 
the same day) provoking appropriate shocks from the ICD. Since the ICD implantation the 
patient was under no medication and remained electrically stable and free of any ICD therapy. 
On admission, the patient was on a febrile status due to pneumonia. All laboratory tests were 
unremarkable. The ECG revealed the typical features of type 1 BS pattern  (Figure 1a) that 
was similar to the ECG after the procainamide test two years ago (Figure 1b). The patient was 
started on oral hydroquinidine hydrochloride (600 mg twice daily), antibiotics and anti-fever 
medication.  He remained electrically stable for the rest of his hospitalization. Of note, on the 
fourth day of hospitalization the characteristic type 1 BS pattern evolved to type 2 (Figure 
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1c). Hydroquinidine was discontinued on the seventh day and the patient was discharged on 
good clinical condition. After nine months of follow-up the patient remained stable without 
any recorded ICD therapy.
Figure 1. First patient: (a) Admission ECG reveals the typical features of type 1 Brugada pattern with a coved 
ST-segment elevation with a downsloping ST segment in V1 and V2, associated T wave inversion and pseudo-
right bundle branch block pattern, (b) ECG after provocative procainamide test two years ago was similar to the  
admission  ECG,  (c)  Evolution  of  Brugada  type  1  to  type  2  after  electrical  stabilization.          
Case  2                                           
A 75-year-old man with BS, who was treated with ICD implantation nine years ago due to 
recurrent  syncope  and  a  subsequent  positive  procainamide  test,  was  admitted  for  seven 
episodes  of  ventricular  fibrillation  within  24  hours  that  was  successfully  treated  with 
appropriate  ICD  shocks.  Since  the  ICD  implantation  the  patient  did  not  receive  any 
medication. There was no predisposing factor that could lead to the electrical instability. All 
laboratory tests were unremarkable. The admission ECG had the typical features of type 1 BS 
pattern (Figure 2a) that was resolved five days later following electrical stabilization with the 
occurence of a new onset right bundle branch block (Figure 2b).
Figure 2. Second patient: (a)     Admission ECG demonstrating a type 1 Brugada pattern with coved ST-segment 
elevation of 3.0 mm with a downsloping ST segment in V1 and V2 and associated T wave inversion, (b) This 
pattern  was  resolved  five  days  later  with  the  occurrence  of  a  new  onset  right  bundle  branch  block.      
The patient  was started on oral hydroquinidine (600 mg twice daily),  remaining electrical 
stable for the rest of his hospitalization.  After six months of hydroquinidine treatment the 
patient was also asymptomatic without any recorded ICD therapy.                                
Discussion
BS is a primary electrical disorder and it is responsible for 20-50% of sudden cardiac deaths in 
patients with structurally normal hearts [1]. At the molecular level the syndrome is associated 
with dysfunction of sodium channels which provokes electrical dysfunction, the characteristic 
ECG pattern and development of arrhythmias.  Of note, patients with suspected BS or family 
mutation  carriers  may  have  normal  ECG.  Diagnostic  provocation  with  a  sodium channel 
blocker, such as ajmaline or procainamide, may usually unmask the BS pattern, verifying the 
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diagnosis [1]. In BS, the prevalence of malignant ventricular arrhythmias varies from 5% in 
asymptomatic patients to 45% in patients with previous cardiac arrest [2]. Electrical  storm 
may be the first  manifestation of the disease.  Unfortunately,  it  is  not accurate  predictable 
which patients  with BS are more prone to develop electrical  storm due to  the absence of 
specific  clinical,  laboratory,  electrocardiographic,  and  electrophysiologic  characteristics 
associated with electrical storm [3]. Fragmented-QRS, late potentials and T-wave alternans 
have been proposed as markers for the substrate for spontaneous VF in BS but with limited 
use in daily clinical practice. [4] Despite our first patient's variations of BS pattern from type 2 
to type 1 (Figure 1) under the existence of a precipitating factor, the BS ECG pattern does not 
seem to be a  predictor  of  outcome in BS patients  [5].                                  
Patient  with VT/VF storm should be recommended for  ICD implant  because none of  the 
antiarrhythmic  drug therapy reliably prevents  sudden cardiac  death.  Both our patients  had 
already been treated with ICD implantation. With regard to the treatment of electrical storm in 
BS the contemporary guidelines suggest isoprenaline and quinidine [IIa and IIb class (level of 
evidence: C)], respectively [6]. Isoprenaline, a β-adrenergic stimulator, increase ICaL function, 
restoring the dome of epicardial action potential and with this mechanism suppresses electrical 
storm and reduces the typical ST elevation [7]. Quinidine, a class IA antiarrhythmic agent, 
blocks the Ito-channel counteracting the marked abbreviation of action potentials in epicardial 
cells and thus normalizing the ECG pattern and ventricular excitability [8].                    
In  our  cases  hydroquinidine  was  administered  for  only  7  days  in  the  first  patient  and 
suppressed the storm, whereas in the second patient the quinidine was continued for 6 months 
contributing to the suppression of the electrical storm and long-term prevention of ventricular 
arrhythmias. Our decision to use hydroquinidine (instead of isoprenaline) for the suppression 
of the electrical storm was based on the ability to administer the drug per os, making it easier 
for  long-term  use.                                         
Recently, a discussion was initiated among electrophysiologists concerning quinidine shortage 
in the drug market [9]. Quinidine is effective medical treatment for patients with short QT 
syndrome, BS and a subgroup of idiopathic ventricular fibrillation [9]. Electrical storms in 
patients with the above syndromes should be treated with ICD. However, since ICD does not 
prevent the occurrence of arrhythmias, oral quinidine could be a reasonable choice for long-
term prevention  of  life-threatening  tachyarrhythmias.                                  
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